| Title |
Randomized double-blind trial of prophylactic topical Evozac® Calming Skin Spray for gefitinib-associated acne-like eruption
|
|---|---|
| Published in |
OncoTargets and therapy, July 2014
|
| DOI | 10.2147/ott.s65961 |
| Pubmed ID | |
| Authors |
Yalan Wang, Yunpeng Yang, Jinxia Xu, Juan Yu, Xia Liu, Ruizhen Gao, Li Zhang |
| Abstract |
"Gefitinib" is a first-generation epidermal growth factor receptor tyrosine-kinase inhibitor. More than half of patients receiving gefitinib develop acne-like eruption. Evozac(®) Calming Skin Spray (Evaux Laboratoires, Évaux-les-Bains, France) is made of Évaux thermal spring water and commonly used for the treatment of dermatological toxicities caused by anti-epidermal growth factor receptor therapy. The aim of the study reported here was to test the effect of Evozac Calming Skin Spray on the prevention of rash in patients receiving gefitinib. |
Mendeley readers
The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 12 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 3 | 25% |
| Unspecified | 2 | 17% |
| Other | 2 | 17% |
| Student > Bachelor | 2 | 17% |
| Lecturer | 1 | 8% |
| Other | 2 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 42% |
| Unspecified | 2 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 8% |
| Psychology | 1 | 8% |
| Business, Management and Accounting | 1 | 8% |
| Other | 2 | 17% |